Davita Inc (NYSE:DVA) – Equities research analysts at SunTrust Banks reduced their FY2018 EPS estimates for Davita in a research note issued to investors on Monday, November 12th. SunTrust Banks analyst D. Macdonald now anticipates that the company will post earnings per share of $3.51 for the year, down from their previous estimate of $3.97. SunTrust Banks also issued estimates for Davita’s Q4 2018 earnings at $0.85 EPS, Q1 2019 earnings at $0.97 EPS, Q2 2019 earnings at $1.10 EPS, Q3 2019 earnings at $1.14 EPS, Q4 2019 earnings at $1.15 EPS and FY2019 earnings at $4.36 EPS.

Several other brokerages have also issued reports on DVA. Raymond James lowered shares of Davita from a “strong-buy” rating to a “market perform” rating in a research report on Thursday, November 8th. ValuEngine raised shares of Davita from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Zacks Investment Research raised shares of Davita from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. TheStreet downgraded shares of Davita from a “b-” rating to a “c+” rating in a research note on Thursday, November 8th. Finally, Royal Bank of Canada raised their price target on shares of Davita from $70.00 to $78.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 8th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. Davita presently has a consensus rating of “Hold” and an average target price of $84.75.

Shares of NYSE DVA opened at $64.64 on Thursday. Davita has a 52-week low of $54.21 and a 52-week high of $80.71. The stock has a market capitalization of $11.32 billion, a PE ratio of 19.47, a P/E/G ratio of 0.88 and a beta of 1.09. The company has a current ratio of 1.84, a quick ratio of 1.82 and a debt-to-equity ratio of 2.09.

Davita (NYSE:DVA) last released its quarterly earnings results on Wednesday, November 7th. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.89 by ($0.33). Davita had a net margin of 5.39% and a return on equity of 13.87%. The firm had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.93 billion. During the same quarter in the prior year, the business posted $0.81 EPS. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year.

Institutional investors have recently added to or reduced their stakes in the company. Captrust Financial Advisors grew its holdings in shares of Davita by 96.8% in the third quarter. Captrust Financial Advisors now owns 3,050 shares of the company’s stock valued at $218,000 after purchasing an additional 1,500 shares in the last quarter. Glenmede Trust Co. NA grew its holdings in shares of Davita by 95.1% in the third quarter. Glenmede Trust Co. NA now owns 658,818 shares of the company’s stock valued at $47,189,000 after purchasing an additional 321,054 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Davita by 275.5% in the third quarter. AQR Capital Management LLC now owns 149,706 shares of the company’s stock valued at $10,723,000 after purchasing an additional 109,835 shares in the last quarter. HRT Financial LLC acquired a new position in Davita during the 3rd quarter worth approximately $376,000. Finally, Point72 Asset Management L.P. grew its holdings in Davita by 165.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 285,100 shares of the company’s stock worth $20,422,000 after acquiring an additional 177,800 shares in the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: Outstanding Shares

Earnings History and Estimates for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.